Cargando…
Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia
BACKGROUND: The most advanced dengue vaccine candidate is a live-attenuated recombinant vaccine containing the four dengue viruses on the yellow fever vaccine backbone (CYD-TDV) developed by Sanofi Pasteur. Several analyses have been published on the safety and immunogenicity of the CYD-TDV vaccine...
Autores principales: | Dorigatti, Ilaria, Aguas, Ricardo, Donnelly, Christl A., Guy, Bruno, Coudeville, Laurent, Jackson, Nicholas, Saville, Melanie, Ferguson, Neil M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504002/ https://www.ncbi.nlm.nih.gov/pubmed/26051515 http://dx.doi.org/10.1016/j.vaccine.2015.05.059 |
Ejemplares similares
-
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America
por: Olivera-Botello, Gustavo, et al.
Publicado: (2016) -
Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam
por: Aguas, R., et al.
Publicado: (2019) -
Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
por: Carpp, Lindsay N., et al.
Publicado: (2020) -
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
por: Forrat, Rémi, et al.
Publicado: (2021) -
Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)